Abstract: Methods for treating and/or SARS-CoV-2 infection are described that inhibit viral replication, multiple protease activities, and provide anti-inflammatory activity. Such activities can be provided by a single species, such as a naturally occurring cyclic peptide.

Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.

Abstract: Peptide analogs of ?-defensins have been developed that are effective in treating multi-drug resistant microbial infections when used at concentrations below those needed to provide a microbicidal effect. These peptides were found to modulate host defense mechanisms to increase clearance of microbial pathogens, enhance phagocytic activity, and enhance neutrophil recruitment while reducing inflammation.

Abstract: Formulations that, when suitably mixed, form edible liquid solutions suitable for blowing bubbles. These formulations contain water, a surfactant, a thickener, a pH adjusting agent/preservative, and optionally a sweetener. The formulations may be provided in either solid form or liquid form, either of which may form an edible bubble solution when mixed with a sufficient quantity of a beverage or similar liquid.

Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.

Abstract: Peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.

Abstract: Uses of novel peptide analogs of a ?-defensin that have been developed which provide a biphasic effect in treating infection and/or sepsis are described. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensin.

Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating infection and/or sepsis. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensin.

Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.

Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating infection and/or sepsis. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensin.

Abstract: A method is provided for a condition related to the activity of a protease through the administration of a ?-defensin, analog, or derivative is described. Suitable proteases include metalloproteases and cysteine proteases such as Cathepsin-C. The ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally.

Abstract: A method is provided for treating bowel disease related to the activity of TNF-?, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.

Abstract: Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a ?-defensin, analog or derivative thereof. Inventive methods include researching ?-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-?)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.

Abstract: Formulations that, when suitably mixed, form edible liquid solutions suitable for blowing bubbles. These formulations contain water, a surfactant, a thickener, a pH adjusting agent/preservative, and optionally a sweetener. The formulations may be provided in either solid form or liquid form, either of which may form an edible bubble solution when mixed with a sufficient quantity of a beverage or similar liquid.

Abstract: A method is provided for treating bowel disease related to the activity of TNF-?, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.

Abstract: A method is provided for inhibiting TACE activity in a human subject, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.

Abstract: A method is provided for inhibiting TACE activity in a human subject, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.

Abstract: Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a ?-defensin, analog or derivative thereof. Inventive methods include researching ?-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-?)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.

Abstract: The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amount of a theta defensin analog to the environment, thereby reducing or inhibiting the growth or survival of the microorganism.

Abstract: The invention provides a method of inhibiting undesirable microbial contamination, invasion, or growth in an individual by administering to the individual an effective amount of a theta defensin. The invention additionally provides a method of inhibiting deleterious effects resulting from microbial contamination, invasion, or growth in an individual by administering to an individual an effective amount of a theta defensin, whereby immune-mediated pathology is limited and immune function is improved.